Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of biosimilar insulin degludec injection versus NovoRapid? No; versus Tresiba brand 诺和达 in adults with type 2 diabetes mellitus
CTR20234192Phase 3Completed
- Sponsor
- Wanbang Biopharmaceuticals
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Wanbang Biopharmaceuticals. Started Sep 2024; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20234192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234192.